HempNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Out-licenses Disruptive Delivery Technology to Strategically Build Cash Flow

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has been strategically out-licensing its disruptive delivery technology and focusing on R&D to improve its value and increase cash flow. An article further discussing the company reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent CFN Media Group interview that his company has gained in value and cash flow, purposely keeping its cash burn rate down and evaluating technology applications for both cannabis and other sectors (http://cnw.fm/4MDyw). … Bunka explained that LXRP is respecting its shareholders in terms of lowered spending and increasing its valuation, purposely maintaining its outstanding share count at relatively low levels. He said that LXRP is building its cash flow through licensing and R&D, as its technology can be used in other sectors besides cannabis. The company is focused on cannabinoid delivery R&D with its DehydraTECH™ technology, which enhances the performance of beneficial compounds in ingestible products, but it can be used across multiple categories, such as nicotine absorption. The result of all this, according to Bunka, is investors that are respected and a valuation of the company that has grown ‘by close to 2,000 percent’ in recent years.”

To view the full article, visit http://cnw.fm/9rL55

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. develops and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the U.S. and Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

More from CannabisNewsBreaks

• HempNewsBreaks – Golden Triangle Ventures Inc. (OTC: GTVH) Restructures $7 Million in Legacy Debt, Secures Repurchase Option
• HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model
• HempNewsBreaks – CannabisNewsWire Named Official Newswire of 2025 Cannabis Means Business Expo in NYC 

About HempWire

HempWire (HW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) HempNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. HW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, HW brings its clients unparalleled visibility, recognition and brand awareness. HW is where news, content and information converge.

For more information please visit https://www.hempwire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.hempwire.com/disclaimer/

HempWire (HW)
Denver, Colorado
www.hempwire.com
303.498.7722 Office
Editor@HempWire.net